Zahler, Stefan - Ludwig-Maximilians-Universität München

研究领域

Angiogenesis, the formation of new blood vessels is important for physiological (e.g. wound healing) and pathological (e.g. tumor growth) processes. We are interested in inhibiting angiogenesis mainly in the tumor context as very promising therapeutic option. The molecular target structures we currently investigate are the kinase CDK5 and the cytoskeleton proteins tubulin and actin. By using and characterizing novel inhibitors of natural origin (e.g. isolated from myxobacteria) we gain insight into basic cell biological questions, and try to establish innovative classes of potential therapeutics. In a further approach, we try to understand basic concepts of angiogenesis by manipulating cellular behaviour via nanoagents. like, e.g. structured surfaces, hygrogels, nanoparticles or artificial membranes.

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Targeting cyclin dependent kinase 5 in hepatocellular carcinoma - a novel therapeutic approach. Ehrlich SM, Liebl J, Ardelt MA, Lehr T, De Toni EN, Mayr D, Brandl L, Kirchner T, Zahler S, Gerbes AL, Vollmar AM. J Hepatol. 2015 Feb 4. pii: S0168-8278(15)00062-8. doi: 10.1016/j.jhep.2015.01.031. [Epub ahead of print] PMID: 25660209. Select item 25391145 The actin targeting compound Chondramide inhibits breast cancer metastasis via reduction of cellular contractility. Menhofer MH, Kubisch R, Schreiner L, Zorn M, Foerster F, Mueller R, Raedler JO, Wagner E, Vollmar AM, Zahler S. PLoS One. 2014 Nov 12;9(11):e112542. doi: 10.1371/journal.pone.0112542. eCollection 2014. Select item 25256790 A small molecule inhibits protein disulfide isomerase and triggers the chemosensitization of cancer cells. Eirich J, Braig S, Schyschka L, Servatius P, Hoffmann J, Hecht S, Fulda S, Zahler S, Antes I, Kazmaier U, Sieber SA, Vollmar AM. Angew Chem Int Ed Engl. 2014 Nov 17;53(47):12960-5. doi: 10.1002/anie.201406577. Epub 2014 Sep 26. PMID: 25256790. Select item 25239826 In vitro and in vivo characterization of the actin polymerizing compound chondramide as an angiogenic inhibitor. Menhofer MH, Bartel D, Liebl J, Kubisch R, Busse J, Wagner E, Müller R, Vollmar AM, Zahler S. Cardiovasc Res. 2014 Nov 1;104(2):303-14. doi: 10.1093/cvr/cvu210. Epub 2014 Sep 19. PMID: 25239826. Select item 25165884 Targeting the actin cytoskeleton: selective antitumor action via trapping PKCɛ. Foerster F, Braig S, Moser C, Kubisch R, Busse J, Wagner E, Schmoeckel E, Mayr D, Schmitt S, Huettel S, Zischka H, Mueller R, Vollmar AM. Cell Death Dis. 2014 Aug 28;5:e1398. doi: 10.1038/cddis.2014.363. PMID: 25165884. Select item 25069048 The pleiotropic profile of the indirubin derivative 6BIO overcomes TRAIL resistance in cancer. Braig S, Bischoff F, Abhari BA, Meijer L, Fulda S, Skaltsounis L, Vollmar AM. Biochem Pharmacol. 2014 Sep 15;91(2):157-67. doi: 10.1016/j.bcp.2014.07.009. Epub 2014 Jul 25. PMID: 25069048. Select item 24679674 Pharmacological characterization of actin-binding (-)-doliculide. Foerster F, Braig S, Chen T, Altmann KH, Vollmar AM. Bioorg Med Chem. 2014 Sep 15;22(18):5117-22. doi: 10.1016/j.bmc.2014.03.003. Epub 2014 Mar 15. PMID: 24679674. Select item 24482380 V-ATPase inhibition regulates anoikis resistance and metastasis of cancer cells. Schempp CM, von Schwarzenberg K, Schreiner L, Kubisch R, Müller R, Wagner E, Vollmar AM. Mol Cancer Ther. 2014 Apr;13(4):926-37. doi: 10.1158/1535-7163.MCT-13-0484. Epub 2014 Jan 30. PMID: 24482380. Select item 24437936 Simplified pretubulysin derivatives and their biological effects on cancer cells. Kubisch R, von Gamm M, Braig S, Ullrich A, Burkhart JL, Colling L, Hermann J, Scherer O, Müller R, Werz O, Kazmaier U, Vollmar AM. J Nat Prod. 2014 Mar 28;77(3):536-42. doi: 10.1021/np4008014. Epub 2014 Jan 17. PMID: 24437936. Select item 24434509 Pretubulysin: a new option for the treatment of metastatic cancer. Braig S, Wiedmann RM, Liebl J, Singer M, Kubisch R, Schreiner L, Abhari BA, Wagner E, Kazmaier U, Fulda S, Vollmar AM. Cell Death Dis. 2014 Jan 16;5:e1001. doi: 10.1038/cddis.2013.510. Select item 24371121 A novel role for inhibitor of apoptosis (IAP) proteins as regulators of endothelial barrier function by mediating RhoA activation. Hornburger MC, Mayer BA, Leonhardt S, Willer EA, Zahler S, Beyerle A, Rajalingam K, Vollmar AM, Fürst R. FASEB J. 2014 Apr;28(4):1938-46. doi: 10.1096/fj.13-235754. Epub 2013 Dec 26. PMID: 24371121. Select item 24285578 Novel tubulin antagonist pretubulysin displays antivascular properties in vitro and in vivo. Kretzschmann VK, Gellrich D, Ullrich A, Zahler S, Vollmar AM, Kazmaier U, Fürst R. Arterioscler Thromb Vasc Biol. 2014 Feb;34(2):294-303. doi: 10.1161/ATVBAHA.113.302155. Epub 2013 Nov 27. Select item 24254321 Regulation of endothelial signaling and migration by v-ATPase. Rath S, Liebl J, Fürst R, Vollmar AM, Zahler S. Angiogenesis. 2014 Jul;17(3):587-601. doi: 10.1007/s10456-013-9408-z. Epub 2013 Nov 20. PMID: 24254321. Select item 24166050 V-ATPase inhibition by archazolid leads to lysosomal dysfunction resulting in impaired cathepsin B activation in vivo. Kubisch R, Fröhlich T, Arnold GJ, Schreiner L, von Schwarzenberg K, Roidl A, Vollmar AM, Wagner E. Int J Cancer. 2014 May 15;134(10):2478-88. doi: 10.1002/ijc.28562. Epub 2013 Nov 14. PMID: 24166050. Select item 24055142 V-ATPase inhibition overcomes trastuzumab resistance in breast cancer. von Schwarzenberg K, Lajtos T, Simon L, Müller R, Vereb G, Vollmar AM. Mol Oncol. 2014 Feb;8(1):9-19. doi: 10.1016/j.molonc.2013.08.011. Epub 2013 Sep 5. PMID: 24055142. Select item 23972628 Determination of the prevalence of whole blood taurine in Irish wolfhound dogs with and without echocardiographic evidence of dilated cardiomyopathy. Vollmar AC, Fox PR, Servet E, Biourge V. J Vet Cardiol. 2013 Sep;15(3):189-96. doi: 10.1016/j.jvc.2013.03.005. Epub 2013 Aug 22. PMID: 23972628 Select item 23946383 Indirubin derivative 6BIO suppresses metastasis. Braig S, Kressirer CA, Liebl J, Bischoff F, Zahler S, Meijer L, Vollmar AM. Cancer Res. 2013 Oct 1;73(19):6004-12. doi: 10.1158/0008-5472.CAN-12-4358. Epub 2013 Aug 14. Select item 23923626 A new perspective on old drugs: non-mitotic actions of tubulin-binding drugs play a major role in cancer treatment. Fürst R, Vollmar AM. Pharmazie. 2013 Jul;68(7):478-83. Review. PMID: 23923626. Select item 23336010 Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors. Weitensteiner SB, Liebl J, Krystof V, Havlíček L, Gucký T, Strnad M, Fürst R, Vollmar AM, Zahler S. PLoS One. 2013;8(1):e54607. doi: 10.1371/journal.pone.0054607. Epub 2013 Jan 15. Select item 23168408 Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. von Schwarzenberg K, Wiedmann RM, Oak P, Schulz S, Zischka H, Wanner G, Efferth T, Trauner D, Vollmar AM. J Biol Chem. 2013 Jan 11;288(2):1385-96. doi: 10.1074/jbc.M112.412007. Epub 2012 Nov 20.